Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Silverback Therapeutics, Inc. was a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC™ technology platform to develop tissue-targeted therapeutics for the treatment of cancer, viral, and fibrotic diseases. Founded in 2016, the company aimed to create potent, locally-acting therapies to improve patient outcomes while minimizing systemic toxicities. In March 2022, Silverback announced a significant restructuring, discontinuing its lead programs. Subsequently, in November 2022, Silverback Therapeutics completed a reverse merger with ARS Pharmaceuticals, with ARS Pharma becoming the surviving entity. Silverback's operations as an independent company ceased thereafter.
The headquarters served as the central hub for research and development, clinical operations, and corporate administration for its ImmunoTAC™ platform.
Located in the South Lake Union neighborhood, known for its concentration of biotech and tech companies, offering modern lab and office spaces typical of the area. Specific architectural details of their leased suite are not widely publicized.
As a clinical-stage biotech, the culture likely emphasized scientific rigor, innovation, collaboration, and a fast-paced environment focused on advancing novel therapies. This is based on typical industry culture; specific details for Silverback are limited post-merger.
The Seattle HQ was strategically important for access to talent, research institutions, and the vibrant biotech ecosystem in the Pacific Northwest during its operational years.
As a U.S.-based clinical-stage biopharmaceutical company primarily focused on research and development, Silverback Therapeutics did not have a significant established global operational presence with international offices. Its collaborations and clinical trials might have involved international partners or sites, typical for the biotechnology industry, but its core team and physical infrastructure were concentrated in the United States prior to its merger.
500 Fairview Ave N, Suite 600
Seattle
WA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Silverback Therapeutics' leadership includes:
Silverback Therapeutics has been backed by several prominent investors over the years, including:
In the 12-18 months preceding its merger with ARS Pharmaceuticals in late 2022, Silverback Therapeutics underwent significant strategic shifts, including program discontinuations and leadership changes. These culminated in the company ceasing independent operations via the merger.
Discover the tools Silverback Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Common email formats for life science companies like Silverback Therapeutics historically included patterns such as [first_initial][last]@[companydomain].com or [first].[last]@[companydomain].com. As Silverback Therapeutics is no longer an active independent entity and its domain (silverbacktx.com) is inactive, these formats are purely historical references.
[first_initial][last]@silverbacktx.com
Format
jdoe@silverbacktx.com
Example
0%
Success rate
ARS Pharmaceuticals / BioSpace • November 23, 2022
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) announced the completion of its previously announced merger with Silverback Therapeutics, Inc. The combined, publicly traded company will operate under the name ARS Pharmaceuticals, Inc. and its shares will trade on the Nasdaq Global Select Market under the ticker symbol 'SPRY'. The merger positions ARS to advance its lead product candidate, neffy® (epinephrine nasal spray)....more
Silverback Therapeutics / GlobeNewswire • July 21, 2022
Silverback Therapeutics, Inc. announced it had entered into a definitive merger agreement with ARS Pharmaceuticals, Inc., a privately-held biopharmaceutical company. The combined company was to focus on advancing ARS’s pipeline of potentially life-saving allergy treatments, including its lead product candidate neffy®....more
Silverback Therapeutics / GlobeNewswire • March 31, 2022
Silverback Therapeutics announced a corporate update, including the decision to discontinue development of its lead clinical programs, SBT6050 and SBT6290, and its discovery program SBT8230. The company initiated a process to explore and evaluate strategic alternatives to maximize shareholder value and also announced a reduction in its workforce by approximately 27%....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Silverback Therapeutics, are just a search away.